Tackling a critical unmet need
Managing pain remains a critical global challenge. While over 300 million annual surgeries often necessitate potent pain relief, the reliance on opioids carries devastating risks of addiction, fueling a societal crisis.
Furthermore, for the estimated 350 million suffering from chronic neuropathic pain, current treatments are tragically ineffective for up to 70% of patients.
This leaves millions underserved, highlighting the urgent need for novel therapies that are both effective and free from the severe side effects and addictive potential plaguing existing options.
Introducing EA1
Using data-driven approaches, we identified a key central neuropeptide system as a target to modulate pain processing. Combining this knowledge with FDA-approved LNP-mRNA technology, we have developed a new non-opioid therapy, EA1, that is effective and long-lasting.
We are currently spinning out from the University of Sydney to move this technology to humans. Join us in helping patients live pain free.
Contact us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!